Ongoing, recruitingTherapeutic exploratory (Phase II)Interventional

ME-401 combined with rituximab-bendamustine for high-risk and rituximab with a 1:1 randomization to ME-401 for low-risk follicular lymphoma as primary treatment: a phase II study – NLG-FL5 (Follicular lymphoma and ME-401: FLAME)

At a glance

Status

Ongoing, recruiting

Phase

Therapeutic exploratory (Phase II)

Sponsor

Karolinska University Hospital

Enrolment target

Start

14 Oct 2022

Age 18 Years to any · Sex: All

Always speak to your GP or specialist before deciding to take part in a study.